Evergreen Capital Management LLC Has $2.75 Million Position in Royalty Pharma plc (NASDAQ:RPRX)

Evergreen Capital Management LLC lowered its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 58.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 107,657 shares of the biopharmaceutical company's stock after selling 149,652 shares during the period. Evergreen Capital Management LLC's holdings in Royalty Pharma were worth $2,746,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of RPRX. Jump Financial LLC bought a new position in Royalty Pharma during the 4th quarter worth approximately $2,088,000. Bridgewater Associates LP bought a new position in shares of Royalty Pharma during the 4th quarter valued at about $1,261,000. Portolan Capital Management LLC increased its stake in Royalty Pharma by 101.9% during the 4th quarter. Portolan Capital Management LLC now owns 344,185 shares of the biopharmaceutical company's stock worth $8,780,000 after purchasing an additional 173,721 shares in the last quarter. Walleye Capital LLC acquired a new stake in Royalty Pharma during the 4th quarter worth approximately $641,000. Finally, Barclays PLC boosted its holdings in shares of Royalty Pharma by 17.6% in the fourth quarter. Barclays PLC now owns 363,308 shares of the biopharmaceutical company's stock valued at $9,269,000 after buying an additional 54,421 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Up 0.6 %

RPRX stock traded up $0.19 during mid-day trading on Tuesday, reaching $32.38. The company had a trading volume of 476,715 shares, compared to its average volume of 3,243,349. The company has a market capitalization of $18.67 billion, a price-to-earnings ratio of 22.33, a PEG ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The stock has a 50 day simple moving average of $32.56 and a two-hundred day simple moving average of $29.32. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RPRX has been the topic of several research reports. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.